Načítá se...
Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A
Hemophilia A, characterized by absent or ineffective coagulation factor VIII (FVIII), is a serious bleeding disorder that entails severe and potentially life-threatening bleeding events. Current standard therapy still involves replacement of FVIII, but is often complicated by the occurrence of neutr...
Uloženo v:
| Vydáno v: | Thromb Haemost |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Georg Thieme Verlag KG
2020
|
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7649063/ https://ncbi.nlm.nih.gov/pubmed/32717759 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1055/s-0040-1714279 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|